BioLineRx files Form D for $3.75 million warrant-related offering
The Israeli biotech reported total proceeds sold of $3,750,000 tied to a registered direct offering and accompanying warrants, according to a Form D filed with the SEC.
SEC filing
Latest
4 stories
Thursday, September 10
Wednesday, September 9
Monday, August 31
BioLineRx closes $3.75 million offering, adds warrant coverage from existing investor
The Israeli biotech priced ADSs and pre-funded warrants at $2.78, with a concurrent private placement of additional warrants covering more than 1.2 billion underlying ordinary shares.
SEC filing (2)